퓨쳐켐
Financials
Valuation Metrics
퓨쳐켐's Market Cap is ₩2021B. At end of 2025 it was ₩6697B. Ranked #817 of 2,436 in KR market (top 34%), #374 of 1,649 on KOSDAQ (top 23%), #90 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 38%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 202.07B KRW | KR#817/2,436 Sec#90/234 |
| Revenue | 19.95B KRW | KR#2,143/2,436 Sec#156/234 |
| Net Income | -7.17B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 69.72B KRW | KR#1,987/2,436 Sec#169/234 |
| Net Assets | 52.79B KRW | KR#1,840/2,436 Sec#156/234 |
| Employees | 87 | KR#1,734/2,436 Sec#136/234 |
| Value | ||
| P/B | 3.83x | KR#2,191/2,436 Sec#179/234 |
| P/S | 10.13x | KR#2,271/2,436 Sec#162/234 |
| FCF Yield | -1.22% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -13.59% | KR#1,962/2,436 Sec#154/234 |
| ROA | -10.29% | KR#2,084/2,436 Sec#162/234 |
| Op. Margin | -40.43% | KR#2,218/2,436 Sec#160/234 |
| Revenue Growth | 25.29% | KR#547/2,436 Sec#53/234 |
| Financial Health | ||
| Debt Ratio | 132.07% | KR#890/2,436 Sec#103/234 |
| Total Debt | 4.75B KRW | KR#1,795/2,436 Sec#173/234 |
| FCF | -2.47B KRW | KR#1,368/2,436 Sec#104/234 |
| Cash | 7.08B KRW | KR#1,856/2,436 Sec#162/234 |
| Current Ratio | 2.54x | KR#739/2,436 Sec#92/234 |
| Performance | ||
| 1Y Return | -47.29% | KR#2,015/2,436 Sec#186/234 |
| 1M Return | -0.98% | KR#996/2,436 Sec#94/234 |
| From 52W High | -73.44% | KR#2,243/2,436 Sec#209/234 |
| 1Y MDD | -79.13% | KR#2,278/2,436 Sec#209/234 |
| Trading | ||
| Volume | 66,984 shares | KR#1,177/2,436 Sec#115/234 |
| Foreign Own. | 7.08% | KR#629/2,436 Sec#60/234 |
| Per Share | ||
| EPS | -484 KRW | KR—/2,436 Sec—/234 |
| BPS | 2,340 KRW | KR#1,951/2,436 Sec#160/234 |
Company Info
FutureChem, a listed corporation, was established in 2001 to manufacture and sell radiopharmaceutical precursors, transferring its listing to the KOSDAQ Market in 2016 after a KONEX Market listing in 2015. The company develops, produces, and sells new radiopharmaceutical drugs, precursors, synthetic reagents, and automated synthesis devices, holding various pipelines including Alzavue for Alzheimer's diagnosis. Its affiliates are FutureChem Healthcare, SI Healthcare, and FutureChem U.S.A. FutureChem is headquartered in Seongdong-gu, Seoul.